Sanofi Lovenox Patent To Return To Court
This article was originally published in The Pink Sheet Daily
Executive Summary
A lower court will reevaluate the validity of a Sanofi-Aventis patent covering its injectable antithrombotic Lovenox (enoxaparin) following a federal court of appeals ruling April 10
You may also be interested in...
Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Lovenox’ Days In Court
Sanofi-Aventis begins a patent challenge case with Sandoz while a similar suit against Amphastar and Teva moves forward.